Oligonucleotide compositions and methods for the modulation of the expression of B7 protein

An antisense compound 8 to 30 nucleobases in length targeted to a 5′-untranslated region, a transcription termination region, a 3′-untranslated region, nucleotides 232-287, nucleotides 324-359, nucleotides 392-472, nucleotides 529-548, nucleotides 593-612, nucleotides 694-713, nucleotides 798-817, nucleotides 900-919, nucleotides 947-998, nucleotides 1035-1054 of a coding region, or nucleotides 148-167 of a transcription initiation region of a nucleic acid molecule of SEQ ID NO:226 encoding a human B7-2 protein, wherein said antisense compound inhibits expression of said human B7-2 protein.

A method of treating an inflammatory disease or condition in an animal comprising administering to said animal a therapeutically effective amount of an antisense compound targeted to a 5′-untranslated region, a transcription termination region, a 3′-untranslated region, nucleotides 334-469 of a coding region, or nucleotides 552-1153 of a coding region of a nucleic acid molecule encoding B7-1 protein under conditions where said antisense compound inhibits expression of said B7-1 protein.

A method of treating an inflammatory disease or condition in an animal comprising administering to said animal a therapeutically effective amount of an antisense compound targeted to a 5′-untranslated region, a transcription termination region, a 3′-untranslated region, nucleotides 240-343 of a coding region, nucleotides 387-1054 of a coding region or nucleotides 133-167 of a transcription initiation region of a nucleic acid molecule encoding B7-2 protein under conditions where said antisense compound inhibits expression of said B7-2 protein.

A method of treating an inflammatory disease or condition in an animal comprising:

• (a) administering to said animal a therapeutically effective amount of an antisense compound targeted to a 5′-untranslated region, a transcription termination region, a 3′-untranslated region, nucleotides 334-469 of a coding region, or nucleotides 552-1153 of a coding region of a nucleic acid molecule encoding B7-1 protein under conditions where said antisense compound inhibits expression of said B7-1 protein;
• and
• (b) administering to said animal a therapeutically effective amount of an antisense compound targeted to a 5′-untranslated region, a transcription termination region, a 3′-untranslated region, nucleotides 240-343 of a coding region, nucleotides 387-1054 of a coding region or nucleotides 133-167 of a transcription initiation region of a nucleic acid molecule encoding B7-2 protein under conditions where said antisense compound inhibits expression of said B7-2 protein.

A method of treating an autoimmune disease or condition in an animal comprising administering to said animal a therapeutically effective amount of an antisense compound targeted to a 5′-untranslated region, a transcription termination region, a 3′-untranslated region, nucleotides 334-469 of a coding region or nucleotides 552-1153 of a coding region of a nucleic acid molecule encoding B7-1 protein under conditions where said antisense compound inhibits expression of said B7-1 protein.

A method of treating an autoimmune disease or condition in an animal comprising administering to said animal a therapeutically effective amount of an antisense compound targeted to a 5′-untranslated region, a transcription termination region, a 3′-untranslated region, nucleotides 240-343 of a coding region, nucleotides 387-1054 of a coding region or nucleotides 133-167 of a transcription initiation region of a nucleic acid molecule encoding B7-2 protein under conditions where said antisense compound inhibits expression of said B7-2 protein.

An antisense oligonucleotide 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human B7-1 comprising at least an 8 nucleobase portion of SEQ ID NO.:

• 26, 36, 128, 129, 132, 135, 136, 145, 146 or 148, wherein said oligonucleotide inhibits expression of human B7-1.

An antisense oligonucleotide 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human B7-2 comprising at least an 8 nucleobase portion of SEQ ID NO.:

• 3, 9, 16, 176, 177, 178, 179, 180, 181, 182, 183, 184, 186, 189, 190, 191, 192, 193, 194, 196, 197, 198, 199, 200 or 201, wherein said oligonucleotide inhibits expression of human B7-2.